Really cool study, not limited by the hematologic toxicity we have seen with other CD47 agents

This was not an easy study to execute, in patients who have few other (if any) treatment options. Here we can appreciate the monotherapy activity with a BiTE over a mAb.

Bispecifics are so in right now. Learn more about them in this recent review: www.nature.com/articles/s41... But now we need to understand a drug 🎯 and the immune system’s complex response modulation in its proximity

#TumorBoardTuesday 🤔Can Claudin 18.2 be used for treatment💊outside of upper GI cancers❓ 📢Join us Tuesday, 02-04-25 at 8PM ET as @ndevitomd.bsky.social & @katherinezhoumd.bsky.social from @dukemedschool.bsky.social 🗣️Claudin 18.2 as a🎯in #pancreaticcancer RT and bring others into the discussion‼️